Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
1 Department of Hepato-Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France.
2 Department of Hepato-Gastroenterology and Gastrointestinal Oncology, CHU Amiens Picardie, Amiens, France.
3 Department of Medical Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France.
4 INSERM, UMR 1138, team 22, Centre de Recherche des Cordeliers, Université de Paris, Paris, France.
5 Department of Gastroenterology, CHU Rennes, INSERM U1242, Rennes, France.
6 Department of Hepato-Gastroenterology, CHU Poitiers, Poitiers, France.
7 Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
8 Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
9 Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
10 Department of Hepato-Gastroenterology, Hôpital Privé Jean Mermoz, Lyon, France.
11 Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
12 Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
13 Department of Medical Oncology, Institut Bergonié, Bordeaux, France. simon.pernot@gmail.com.